EP1718669A4 - IDENTIFICATION OF NEW IGE EPITOPES - Google Patents

IDENTIFICATION OF NEW IGE EPITOPES

Info

Publication number
EP1718669A4
EP1718669A4 EP04779424A EP04779424A EP1718669A4 EP 1718669 A4 EP1718669 A4 EP 1718669A4 EP 04779424 A EP04779424 A EP 04779424A EP 04779424 A EP04779424 A EP 04779424A EP 1718669 A4 EP1718669 A4 EP 1718669A4
Authority
EP
European Patent Office
Prior art keywords
identification
ige epitopes
novel ige
novel
epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04779424A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1718669A1 (en
Inventor
Sanjaya Singh
Danyang Huang
Sek Chung Michael Fung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/002894 external-priority patent/WO2004070011A2/en
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of EP1718669A1 publication Critical patent/EP1718669A1/en
Publication of EP1718669A4 publication Critical patent/EP1718669A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP04779424A 2004-02-02 2004-07-29 IDENTIFICATION OF NEW IGE EPITOPES Withdrawn EP1718669A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2004/002894 WO2004070011A2 (en) 2003-02-01 2004-02-02 HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES
PCT/US2004/002892 WO2004070010A2 (en) 2003-02-01 2004-02-02 A method for generating high affinity antibodies
PCT/US2004/024360 WO2005075504A1 (en) 2004-02-02 2004-07-29 IDENTIFICATION OF NOVEL IgE EPITOPES

Publications (2)

Publication Number Publication Date
EP1718669A1 EP1718669A1 (en) 2006-11-08
EP1718669A4 true EP1718669A4 (en) 2007-10-10

Family

ID=34841291

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04779424A Withdrawn EP1718669A4 (en) 2004-02-02 2004-07-29 IDENTIFICATION OF NEW IGE EPITOPES

Country Status (8)

Country Link
EP (1) EP1718669A4 (ko)
JP (1) JP2008507474A (ko)
KR (4) KR101365375B1 (ko)
CN (1) CN102702359A (ko)
AU (2) AU2004315197B2 (ko)
CA (1) CA2552999A1 (ko)
SG (2) SG149892A1 (ko)
WO (1) WO2005075504A1 (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009545330A (ja) * 2006-08-04 2009-12-24 ザ トラスティーズ オブ ザ ユニバーシティー オブ ぺンシルべニア Ige依存性疾患を治療するための方法および組成物
US7833527B2 (en) * 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
AR065368A1 (es) * 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
JP2010519194A (ja) * 2007-02-15 2010-06-03 アストラゼネカ・アクチエボラーグ IgE分子に対する結合要素
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
AP2010005296A0 (en) * 2007-12-21 2010-06-30 Glaxosmithkline Biolog Sa Vaccines for malaria
EP2376108B1 (en) 2008-12-09 2017-02-22 Pfizer Vaccines LLC IgE CH3 PEPTIDE VACCINE
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
EP3565587A4 (en) * 2017-01-06 2020-12-16 The Regents of The University of California THERAPEUTIC ANTI-IGE ANTIBODIES AND RELATED METHODS AND COMPOSITIONS
AU2019244666A1 (en) * 2018-03-26 2020-10-08 Novartis Ag Methods of treating chronic spontaneous urticaria using ligelizumab
EP4355362A1 (en) 2021-06-14 2024-04-24 Novartis AG Pharmaceutical formulation containing an anti-ige antibody

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263655A2 (en) * 1986-10-03 1988-04-13 Dainippon Pharmaceutical Co., Ltd. Novel peptides having antiallergic activity
EP0957111A2 (en) * 1998-04-09 1999-11-17 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
WO2000023477A2 (en) * 1998-10-20 2000-04-27 University Of Sheffield Immunoglobulin variants
WO2000050461A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
WO2000074716A2 (en) * 1999-06-08 2000-12-14 Smithkline Beecham Biologicals S.A. Ige peptides for allergy immunotherapy
WO2002016409A2 (en) * 2000-08-22 2002-02-28 Glaxosmithkline Biologicals S.A. Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies
EP1195161A2 (en) * 2000-08-30 2002-04-10 Pfizer Products Inc. Anti-IgE vaccines
WO2002034288A2 (en) * 2000-10-27 2002-05-02 Smithkline Beecham Biologicals S.A. Vaccine for treating allergy
EP1262491A2 (en) * 2001-05-22 2002-12-04 Pfizer Products Inc. Non-anaphylactogenic IgE vaccines
WO2003092714A2 (en) * 2002-04-30 2003-11-13 Glaxosmithkline Biologicals S.A. Peptide variants of ige constrained by beta-lactam bond

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0589840T3 (da) * 1992-09-24 2004-07-26 Novartis Ag Omdannede monoklonale antistoffer mod en immunoglobulinisotype
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
CN1829806A (zh) * 2003-02-01 2006-09-06 唐纳士公司 产生高亲和力抗体的方法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263655A2 (en) * 1986-10-03 1988-04-13 Dainippon Pharmaceutical Co., Ltd. Novel peptides having antiallergic activity
EP0957111A2 (en) * 1998-04-09 1999-11-17 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
WO2000023477A2 (en) * 1998-10-20 2000-04-27 University Of Sheffield Immunoglobulin variants
WO2000050461A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
WO2000074716A2 (en) * 1999-06-08 2000-12-14 Smithkline Beecham Biologicals S.A. Ige peptides for allergy immunotherapy
WO2002016409A2 (en) * 2000-08-22 2002-02-28 Glaxosmithkline Biologicals S.A. Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies
EP1195161A2 (en) * 2000-08-30 2002-04-10 Pfizer Products Inc. Anti-IgE vaccines
WO2002034288A2 (en) * 2000-10-27 2002-05-02 Smithkline Beecham Biologicals S.A. Vaccine for treating allergy
EP1262491A2 (en) * 2001-05-22 2002-12-04 Pfizer Products Inc. Non-anaphylactogenic IgE vaccines
WO2003092714A2 (en) * 2002-04-30 2003-11-13 Glaxosmithkline Biologicals S.A. Peptide variants of ige constrained by beta-lactam bond

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHANG T W ET AL: "MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN IGE-PRODUCING B CELLS A POTENTIAL THERAPEUTIC FOR IGE-MEDIATED ALLERGIC DISEASES", BIO-TECHNOLOGY (NEW YORK), vol. 8, no. 2, 1990, pages 122 - 126, XP009084134, ISSN: 0733-222X *
MACGLASHAN D W ET AL: "DOWN-REGULATION OF FCEPSILONRI EXPRESSION ON HUMAN BASOPHILS DURINGIN VIVO TREATMENT OF ATOPIC PATIENTS WITH ANTI-IGE ANTIBODY", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 158, 1997, pages 1438 - 1445, XP002930932, ISSN: 0022-1767 *
See also references of WO2005075504A1 *

Also Published As

Publication number Publication date
KR101562114B1 (ko) 2015-11-20
SG149892A1 (en) 2009-02-27
KR20120056297A (ko) 2012-06-01
AU2009202408A1 (en) 2009-07-09
KR20140021058A (ko) 2014-02-19
CA2552999A1 (en) 2005-08-18
AU2004315197A1 (en) 2005-08-18
KR20130088198A (ko) 2013-08-07
KR101365375B1 (ko) 2014-02-19
EP1718669A1 (en) 2006-11-08
KR20070008578A (ko) 2007-01-17
KR101581659B1 (ko) 2015-12-31
SG183683A1 (en) 2012-09-27
JP2008507474A (ja) 2008-03-13
AU2004315197B2 (en) 2009-06-04
CN102702359A (zh) 2012-10-03
WO2005075504A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
IL176940A0 (en) IDENTIFICATION OF NOVEL IgE EPITOPES
GB0412973D0 (en) Identification of antibody producing cells
ZA200609595B (en) Novel CIS-Imidazolines
IL179730A0 (en) Novel cis-imidazolines
EP1778618A4 (en) SYNTHESIS OF TRIETHYLENETETRAMINES
IL211491A0 (en) 4-(benzimidazolylmethylamino)-benzamidines
TWI372750B (en) Novel hydroxy-6-heteroarylphenanthridines
IL179811A0 (en) Identification of tumors
EP1869192A4 (en) FRAME MIXTURE OF ANTIBODIES
EP1965341A4 (en) CARD WITH THE ABILITY TO AUTHENTICATE
EP1711484A4 (en) SYNTHESIS OF CYANOIMINO-BENZOIMIDAZOLES
HK1081282A1 (en) Chronograph
GB0426160D0 (en) Production of proteins
EP1718669A4 (en) IDENTIFICATION OF NEW IGE EPITOPES
HK1087494A1 (en) Wristwatch case
IL183106A0 (en) Production of proteins
ZA200610303B (en) Novel cis-imidazolines
IL178184A0 (en) Synthesis of pyrrole-2-carbonitriles
GB0505985D0 (en) Nail aid
ZA200606635B (en) Novel isoamido-substituted hydroxy-6-phenylphenanthridines
AU158223S (en) Wristwatch
GB0408865D0 (en) Novel benzoxazocines
GB0424519D0 (en) Identification of micro-organisms
GB0413479D0 (en) Novel antibodies
ZA200508325B (en) Manufacture of kerbstones

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060824

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20070912

17Q First examination report despatched

Effective date: 20090407

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130625